Zachary Schonrock

发表

Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia

B. Druker, Theodore P. Braun, Cody Coblentz, 2020, Proceedings of the National Academy of Sciences.

Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors

E. Demir, B. Druker, H. Mohammed, 2022, Leukemia.

Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms

B. Druker, Theodore P. Braun, Adrian Baris, 2021, bioRxiv.

Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia

Michal R. Grzadkowski, S. McWeeney, R. Ries, 2022, Nature Communications.

Metabolic model for diversity-generating biosynthesis

Elizabeth Pierce, B. Bachmann, B. Olivera, 2016, Proceedings of the National Academy of Sciences.

Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia

Theodore P. Braun, Cody Coblentz, J. Maxson, 2021, bioRxiv.

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia

Michal R. Grzadkowski, S. McWeeney, R. Ries, 2019, Nature Communications.

Correction: Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia

Theodore P. Braun, Cody Coblentz, J. Maxson, 2022, Leukemia.

RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development

Theodore P. Braun, Cody Coblentz, J. Maxson, 2023, Leukemia.

ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II

B. Druker, H. Mohammed, T. Lusardi, 2020, bioRxiv.

Recurrent mutations in the epigenetic regulator Additional Sex-Combs Like 1 ( ASXL 1 ) are associated with universally poor prognosis in myeloid malignancy

A. Lusardi, B. Druker, H. Mohammed, 2022 .